News | September 29, 2025
AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
The medicine was well tolerated, with no unexpected safety issue
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Subscribe To Our Newsletter & Stay Updated
